A similar result was found by Balko et al. who applied a gene signature predicting the sensitivity to EGFR tyrosine kinase inhibitors obtained from various cell lines to classify human lung adenocarcinomas [6]. This evidence concerns the gene EGFR and lung adenocarcinoma.